Floatz logo

Recombinant Human EGF-rP64K

PD-L1 Positive

Roswell Park Cancer InstitutePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the PD-L1 Positive cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Gilead Sciences
Phase 3B
Pembrolizumab
Gilead Sciences
Phase 3B
Epirubicin
Gilead Sciences
Phase 3B
Carboplatin
Gilead Sciences
Phase 3B
Limertinib
Shanghai Chest Hospital
Phase 2CCC

View all 12 →

Same molecule, other indications

Recombinant Human EGF-rP64K is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
lung cancerDormant
BB
Indicative ·
65 / 100
View asset →
head and neck squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →